Product Description
Clioquinol is an orally bioavailable, lipophilic, copper-binding, halogenated 8-hydroxyquinoline with antifungal, antiparasitic and potential antitumor activities. Clioquinol forms a stable chelate with copper (copper (II) ions), which inhibits the chymotrypsin-like activity of the proteasome; consequently, ubiquitinated proteins may accumulate in tumor cells, followed by tumor cell apoptosis and the inhibition of tumor angiogenesis. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Clioquinol)
Mechanisms of Action: DNA Replication Inhibitor,Fungal Growth Inhibitor,Copper Chelator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical,Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Australia | Bangladesh | Brazil | Bulgaria | Canada | Chile | Colombia | Cyprus | Denmark | Dominican Republic | Ecuador | Egypt | France | Germany | Hong Kong | India | Indonesia | Ireland | Italy | Malta | Mexico | Netherlands | New Zealand | Pakistan | Peru | Philippines | Portugal | Russia | Slovenia | South Africa | Spain | Sri Lanka | Taiwan | Turkey | United Kingdom | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: EMS
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Drug Resistant Epilepsy
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| CLIOKIDA | P2 |
Recruiting |
Drug Resistant Epilepsy |
2025-12-31 |
2025-05-02 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/28/2021 |
News Article |
Alfa Chemistry Announces to Provide Pharmaceuticals, Illicit Drugs & Alcohol Standards |